Fig. 3.

Influence on platelet aggregation of the antiangiogenic agents sunitinib and bevacizumab in patients. a Ex vivo platelet aggregation 24 h and 3 weeks after the first administration of sunitinib. PRP was activated with ADP (2.5–10 μM) or collagen (0.25–1.0 μg/ml). On the X-axis the time points are represented, on the Y-axis the percentage of aggregation compared to pretreatment (Collagen: pretreatment N = 8; 24 h N = 8, 3wk N = 5. ADP; pretreatment N = 11; 24 h: N = 11; 3wk N = 7)*. b Ex vivo platelet aggregation on day one, and 3 to 5 days after the administration of bevacizumab. PRP was activated with ADP or collagen. On the X-axis the time points are represented, on the Y-axis the percentage of aggregation compared to pretreatment (Collagen: pretreatment N = 6, 5 h: N = 4, 3–5 days: N = 6. ADP: pretreatment N = 7, 5 h: N = 5, 3–5 days N = 7). The error bars represent the standard error of mean. * = p ≤ 0.05, *** = p ≤ 0.001. *One patient with sunitinib had thrombocytosis, and we were unable to dilute the PRP beneath 6 × 10¹¹ platelets/L (we therefore kept the concentration equivalent for all visits)